Short communication: B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-α response to TLR9 triggering

AIDS Research and Human Retroviruses

Volumn 26, Issue 10, 2010, Pages 1063-1074

  Audigé, Annette ^a   Schlaepfer, Erika ^a   Von Wyl, Viktor ^a   Miller, Regina C ^a   Vernazza, Pietro ^b   Nadal, David ^c   Speck, Roberto F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; INTERLEUKIN 6; LATENT MEMBRANE PROTEIN 1; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; B7 ANTIGEN; CPG ODN 2006; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; B CELL LYMPHOMA; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM TUMOR; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOGENICITY; VIROLOGY;

ADULT; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM NEOPLASMS; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 77958495174     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0288     Document Type: Article

References (39)

1. Carbone A and Gloghini A: AIDS-related lymphomas: From pathogenesis to pathology. Br J Haematol 2005;130(5):662-670.
2. Gates AE and Kaplan LD: Biology and management of AIDS-associated non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2003;17(3):821-841.
3. Levine AM, Sullivan-Halley J, Pike MC, et al.: Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991;68(11):2466-2472.
4. Hoang-Xuan K, Camilleri-Broet S, and Soussain C: Recent advances in primary CNS lymphoma. Curr Opin Oncol 2004;16(6):601-606.
5. Cheung MC, Pantanowitz L, and Dezube BJ: AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005;10(6):412-426.
6. MacMahon EM, Glass JD, Hayward SD, et al.: Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991;338(8773):969-973.
7. Larocca LM, Capello D, Rinelli A, et al.: The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998;92(3):1011-1019.
8. Anthony IC, Crawford DH, and Bell JE: B lymphocytes in the normal brain: Contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain 2003;126(Pt 5):1058-1067.
9. Hickey WF: Basic principles of immunological surveillance of the normal central nervous system. Glia 2001;36(2):118-124.
10. Gasser O, Bihl FK, Wolbers M, et al.: HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med 2007;4(3):e96.
11. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1365-1371.
12. Schindler M, Munch J, Kutsch O, et al.: Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006;125(6):1055-1067.
13. Bafica A, Scanga CA, Schito M, Chaussabel D, and Sher A: Influence of coinfecting pathogens on HIV expression: Evidence for a role of Toll-like receptors. J Immunol 2004;172(12):7229-7234.
14. Baenziger S, Heikenwalder M, Johansen P, et al.: Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 2009;113(2):377-388.
15. Mogensen TH: Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009;22(2):240-273.
16. Bochud PY, Hersberger M, Taffe P, et al.: Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007;21(4):441-446.
17. Oh DY, Taube S, Hamouda O, et al.: A functional Toll-like receptor 8 variant is associated with HIV disease restriction. J Infect Dis 2008;198(5):701-709.
18. Rochford R, Cannon MJ, and Moormann AM: Endemic Burkitt's lymphoma: A polymicrobial disease? Nat Rev Microbiol 2005;3(2):182-187.
19. Gazzinelli RT and Denkers EY: Protozoan encounters with Toll-like receptor signalling pathways: Implications for host parasitism. Nat Rev Immunol 2006;6(12):895-906.
20. Parroche P, Lauw FN, Goutagny N, et al.: Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 2007;104(6):1919- 1924.
21. Ladell K, Dorner M, Zauner L, et al.: Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell Microbiol 2007;9(8):2055-2069.
22. Kandimalla ER, Bhagat L, Li Y, et al.: Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists. Proc Natl Acad Sci USA 2005;102(19):6925-6930.
23. Gantner F, Hermann P, Nakashima K, Matsukawa S, Sakai K, and Bacon KB: CD40-dependent and-independent activation of human tonsil B cells by CpG oligodeoxynucleotides. Eur J Immunol 2003;33(6):1576-1585.
24. Hanten JA, Vasilakos JP, Riter CL, et al.: Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol 2008;9:39.
25. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
26. Vollmer J: Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Expert Opin Biol Ther 2005;5(5):673-682.
27. Jiang W, Lederman MM, Mohner RJ, et al.: Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol 2008;82(16):7837-7845.
28. Moir S and Fauci AS: B cells in HIV infection and disease. Nat Rev Immunol 2009;9(4):235-245.
29. Greenwald RJ, Freeman GJ, and Sharpe AH: The B7 family revisited. Annu Rev Immunol 2005;23:515-548.
30. Kaufmann DE, Kavanagh DG, Pereyra F, et al.: Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007;8(11):1246-1254.
31. Malaspina A, Moir S, Kottilil S, et al.: Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol 2003;170(12):5965- 5972.
32. Martinson JA, Tenorio AR, Montoya CJ, et al.: Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology 2007;120(4):526-535.
33. Ballet JJ, Sulcebe G, Couderc LJ, et al.: Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin Exp Immunol 1987;68(3):479-487.
34. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, and Clements ML: The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989;262(6):779-783.
35. Opravil M, Fierz W, Matter L, Blaser J, and Luthy R: Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991;84(2):185-189.
36. Breen EC, van der Meijden M, Cumberland W, Kishimoto T, Detels R, and Martinez-Maza O: The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999;92(3):293-299.
37. Pluda JM, Venzon DJ, Tosato G, et al.: Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993;11(6):1099-1107.
38. Cozen W, Gill PS, Ingles SA, et al.: IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004;103(8):3216- 3221.
39. Moller B and Villiger PM: Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 2006;27(4):391-408.